InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: mjw007 post# 441

Monday, 10/17/2016 4:15:41 PM

Monday, October 17, 2016 4:15:41 PM

Post# of 2099
rGBM is a tough nut to crack. Not many will invest in VB-111 because of this, and short sellers will sell based on this statistic. The odds are HEAVILY stacked against VB-111 being successful (in extending OS). If prior drugs have had success against rGBM then I think you'd see the stock at around $10-15 based on potential.

If VB-111 is effective, it'll be the first one to claim that it can improve survival.

Even avastin cannot claim this - "Currently, no data have shown whether or not Avastin improves disease-related symptoms or survival in people with rGBM."
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News